Sana Biotechnology (NASDAQ:SANA) Upgraded to Hold at Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities research analysts also recently issued research reports about the company. HC Wainwright cut their price objective on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. JMP Securities set a $8.00 price objective on shares of Sana Biotechnology in a research note on Thursday, October 30th. Finally, Wedbush upped their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Price Performance

Shares of SANA stock traded up $0.04 during trading hours on Friday, hitting $4.09. The company had a trading volume of 5,461,342 shares, compared to its average volume of 6,789,225. The stock has a market capitalization of $972.63 million, a PE ratio of -4.22 and a beta of 1.94. The company’s fifty day moving average is $4.06 and its 200 day moving average is $3.34. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.03. Equities analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SANA. Bank of New York Mellon Corp increased its stake in Sana Biotechnology by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock valued at $578,000 after purchasing an additional 7,230 shares during the last quarter. Cerity Partners LLC grew its position in shares of Sana Biotechnology by 200.3% in the 1st quarter. Cerity Partners LLC now owns 46,181 shares of the company’s stock valued at $78,000 after buying an additional 30,801 shares during the last quarter. CWM LLC raised its stake in Sana Biotechnology by 290.7% during the 1st quarter. CWM LLC now owns 38,431 shares of the company’s stock worth $65,000 after acquiring an additional 28,595 shares in the last quarter. Summit X LLC acquired a new stake in Sana Biotechnology during the 1st quarter worth $60,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its position in Sana Biotechnology by 52.7% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 289,273 shares of the company’s stock valued at $483,000 after acquiring an additional 99,801 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.